The Lack of a Standardized Definition of Chronic Dialysis Treatment in German Statutory Health Insurance Claims Data

被引:1
|
作者
Bothe, Tim [1 ]
Fietz, Anne-Katrin [1 ,2 ]
Mielke, Nina [1 ]
Freitag, Julia [3 ]
Ebert, Natalie [1 ]
Schaeffner, Elke [1 ]
机构
[1] Charite Univ Med Berlin, Inst Publ Hlth, Charitepl 1, D-10117 Berlin, Germany
[2] Charite Univ Med Berlin, Inst Biometry & Clin Epidemiol, Berlin, Germany
[3] AOK Nordost Die Gesundheitskasse, Potsdam, Germany
来源
DEUTSCHES ARZTEBLATT INTERNATIONAL | 2024年 / 121卷 / 05期
关键词
PATIENTS STARTING DIALYSIS; MORTALITY; DEPRESSION; MANAGEMENT; DISEASE; SCORE; CARE;
D O I
10.3238/arztebl.m2024.0015
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Chronic kidney failure (CKF) is often treated with dialysis, which is invasive and costly and carries major medical risks. The existing studies of patients with CKF requiring dialysis that are based on claims data from German statutory health insurance (SHI) carriers employ varying definitions of this entity, with unclear consequences for the resulting statistical estimates. Methods: We carried out a cohort study on four random samples, each consisting of 62 200 persons aged 70 or above, from among the insurees of the SHI AOK Nordost, with one sample for each of the years 2012, 2014, 2016, and 2018. The prevalence, incidence, mortality, and direct health care costs of CKF requiring dialysis were estimated and compared on the basis of four different definitions from literature and a new definition developed by the authors in reference to billing data. Results: The different definitions led to variation in 12-month prevalences (range: 0.33-0.61%) and 6-month incidences (0.058-0.100%). The percentage of patients with prior acute kidney injury (AKI) ranged from 27.6% to 61.8%. Among incident patients, three-month survival ranged from 70.2% to 88.1%, and six-month survival from 60.5% to 81.3%. In CKF patients without prior AKI, the survival curves differed less across definitions (80.2-91.8% at three months, 70.7-84.4% at six months). The monthly health care costs ranged from <euro>6010 to <euro>9606, with marked variability across definitions in the costs of inpatient and outpatient care. Conclusion: The lack of a standardized definition of CKF requiring dialysis in German SHI claims data leads to variability in the estimated case numbers, mortality, and health care costs. These differences are most probably in part due to the variable inclusion of inpatients who received short-term dialysis after AKI.
引用
收藏
页码:148 / 154
页数:18
相关论文
共 50 条
  • [1] Non-standardized definition of chronic dialysis within German health claims data results in varying estimates for incidence and mortality
    Ebert, Natalie
    Bothe, Tim
    Fietz, Anne-Katrin
    Mielke, Nina
    Freitag, Julia
    Schaeffner, Elke
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2024, 39 : I1378 - I1379
  • [2] Diagnosing and Diagnosis Coding of Dementias in Claims Data from German Statutory Health Insurance
    Kaduszkiewicz, Hanna
    Wiese, Birgitt
    Steinmann, Susanne
    Schoen, Gerhard
    Hoffmann, Falk
    van den Bussche, Hendrik
    PSYCHIATRISCHE PRAXIS, 2014, 41 (06) : 319 - 323
  • [3] CUTANEOUS LYMPHOMAS IN GERMANY: LANDSCAPING ANALYSIS OF GERMAN STATUTORY HEALTH INSURANCE (SHI) CLAIMS DATA
    Doess, A.
    Jadasz, J.
    Zech, I. M.
    May, M.
    Feig, C.
    Hibbe, T.
    VALUE IN HEALTH, 2019, 22 : S735 - S735
  • [4] BIG DATA ANALYSIS OF CANCER TREATMENT IN GERMANY - MAPPING OF TREATMENT LANDSCAPE BASED ON A GERMAN STATUTORY HEALTH INSURANCE (SHI) CLAIMS DATA ANALYSIS
    May, M.
    Schellong, S.
    Bruchhausen, Y.
    Kretzschmar, A.
    Riess, H.
    VALUE IN HEALTH, 2018, 21 : S64 - S64
  • [5] Hepatocellular carcinoma after prior sorafenib treatment: incidence, healthcare utilisation and costs from German statutory health insurance claims data
    Johannes Clouth
    Astra M. Liepa
    Guido Moeser
    Heiko Friedel
    Magdalena Bernzen
    Jörg Trojan
    Elena Garal-Pantaler
    Health Economics Review, 8
  • [6] Hepatocellular carcinoma after prior sorafenib treatment: incidence, healthcare utilisation and costs from German statutory health insurance claims data
    Clouth, Johannes
    Liepa, Astra M.
    Moeser, Guido
    Friedel, Heiko
    Bernzen, Magdalena
    Trojan, Joerg
    Garal-Pantaler, Elena
    HEALTH ECONOMICS REVIEW, 2018, 8
  • [7] Identification of Chronic Migraineurs in Health Insurance Claims Data
    Berger, A.
    Corbell, C.
    Moynahan, A. P.
    Messali, A.
    Oster, G.
    Silberstein, S.
    HEADACHE, 2014, 54 : 17 - 17
  • [8] Prolonged treatment of patients with cancer associated thromboembolism (CAT). mapping of treatment landscape based on a German statutory health insurance (SHI) claims data analysis [CERTIFICAT]
    Kretzschmar, Albrecht
    May, Melanie
    Heinken, Andreas
    Riess, Hanno
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [9] Anticoagulant treatment of patients with cancer associated thromboembolism (CAT). Mapping of treatment landscape based on a German Statutory Health Insurance (SHI) claims data analysis [CERTIFICAT]
    Heinken, A.
    Kretzschmar, A.
    May, M.
    Riess, H.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 216 - 216
  • [10] Hidradenitis suppurativa - prevalence analyses of German statutory health insurance data
    Schneider-Burrus, S.
    Lux, G.
    van der Linde, K.
    Barbus, S.
    Huss-Marp, J.
    Tsaousi, A.
    Wasem, J.
    Wolff, B.
    Sabat, R.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2021, 35 (01) : E32 - E35